A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

NCT01231516 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

724

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: GSK1349572
DRUG: Raltegravir
DRUG: GSK1349572 Placebo
DRUG: Raltegravir Placebo

Sponsor

ViiV Healthcare

Collaborators

[object Object]
[object Object]